Bioimpedance-guided fluid management for decompensated heart failure
Bioimpedance Integration for Optimized Fluid Management in Decompensated Heart Failure
This test sees if using bedside bioimpedance measurements to guide diuretic treatment helps people hospitalized with worsening heart failure manage fluid and reduce extra treatment or rehospitalization within 90 days.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 255 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mid and South Essex NHS Foundation Trust Academic / other |
| Locations | 1 site (Basildon, Essex) |
| Trial ID | NCT07173426 on ClinicalTrials.gov |
What this trial studies
Hospitalized adults with decompensated heart failure are randomly assigned to either a group where bioimpedance analysis (BIA) is used serially to guide diuretic therapy or a standard care group where BIA is measured but not shared with the clinical team. The BIA-guided group receives measurements within 24 hours of admission and throughout the hospital stay to inform fluid management decisions, while the control group follows usual clinical assessment. The main outcome is whether BIA guidance reduces the need for additional diuretic treatment or rehospitalization for heart failure within 90 days after discharge. The trial is conducted at Basildon University Hospital and excludes patients on renal replacement therapy, in intensive care, on palliative pathways, or enrolled in other interventional heart failure trials.
Who should consider this trial
Good fit: Adults (over 18) admitted to hospital with a decompensated episode of heart failure who can give informed consent and are not in intensive care, on renal replacement therapy, or on a palliative pathway are the ideal candidates.
Not a fit: Patients on renal replacement therapy, those receiving intensive care, those on a palliative care pathway with limited life expectancy, or those already in other interventional heart failure trials are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, this approach could reduce repeat hospital admissions and unnecessary extra diuretic treatments by improving bedside fluid management.
How similar studies have performed: Smaller prior studies have suggested BIA-guided therapy can improve fluid management and lower biomarkers like NT-proBNP, but large randomized evidence in hospitalized decompensated heart failure is limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18 years 2. Patients with hospitalised with a decompensated episode of Heart Failure regardless of Ejection Fraction 3. Able and willing to consent. Exclusion Criteria: 1. Patients on a palliative care pathway and/or estimated life expectancy \<3 months 2. Patients admitted to ITU/ on intensive care support. 3. Patients currently taking part in any trials investigating new heart failure drug or interventional treatment. 4. Patients requiring Renal Replacement Therapy. 5. Patients unable or unwilling to give consent.
Where this trial is running
Basildon, Essex
- Basildon University Hospital — Basildon, Essex, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Henry Oluwasefunmi Savage, MD FRCP
- Email: henry.savage@nhs.net
- Phone: +44 01268524900
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.